W. Scott Harkonen, M.D., is President and Chief Executive Officer of CoMentis, a pharmaceutical company engaged in the discovery and development of small-molecule drugs to treat Alzheimer’s disease, age-related macular degeneration (AMD) and cognitive disorders.

Read the rest of this entry »

Dr. Shelley Chu joined Frazier Healthcare in 2005 as a Vice President and became a Principal in 2007.  Dr. Chu is a member of Frazier Healthcare’s biopharma investment team and has played significant roles in the firm’s investments in Intradigm Corporation, Cadence Pharmaceuticals, Cerexa, and Arete Therapeutics among others.  Read the rest of this entry »

Dr. Steven Targum serves as Chief Medical Officer at BrainCells, Inc. (BCI), a biopharmaceutical company focused on the development of breakthrough small molecule therapeutics for diseases of the central nervous system (CNS).  Read the rest of this entry »

I just sat down at my computer and answered 298 questions about myself as part of a career development assessment. The questions were straightforward, and the process only took about 45 minutes. Now I am waiting for the results, intrigued and a bit intimidated by what I might find out about myself. Read the rest of this entry »

Martin Tolar, M.D., Ph.D., is Chief Scientific Officer at CoMentis, a pharmaceutical company engaged in the discovery and development of small-molecule drugs to treat Alzheimer’s disease, age-related macular degeneration (AMD) and cognitive disorders. Read the rest of this entry »

Dr. Yamada joined Frazier Healthcare Ventures in 2006 as a Senior Advisor to the biopharma team. Read the rest of this entry »

Henry Hsu, M.D., Chief Medical Officer, CoMentis, a pharmaceutical company engaged in the discovery and development of small-molecule drugs to treat Alzheimer’s disease, age-related macular degeneration (AMD) and cognitive disorders. Read the rest of this entry »

August M. Watanabe, MD, joined Frazier Healthcare Ventures in 2005 as Senior Advisor to the Biopharma team.   Read the rest of this entry »

MedImmune Ventures, Inc. is a wholly owned venture capital subsidiary of MedImmune, Inc. It was created in 2002 to leverage the company’s expertise in discovering, developing and commercializing biotechnology products, as well as its financial resources, to transform new ideas in biotechnology into successful products and companies. Read the rest of this entry »

Joe Amprey is a member of the Metastatix Board of Directors and is also a Principal at MedImmune Ventures. Read the rest of this entry »